Literature DB >> 20719449

Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis.

Ewa Szymańska1, Michał J Markuszewski, Marcin Markuszewski, Roman Kaliszan.   

Abstract

Metabolic profiles of nucleosides studied on the level of urine are closely related to the pathophysiological status of the organism. Posttranscriptional modifications of RNA (mostly tRNA) in cell nucleus are responsible for change of nucleoside levels during malignant disease. In this paper, 256 metabolite profiles from 160 urogenital tract cancer patients and 96 healthy controls, composed of 19 nucleosides were collected and studied with the application of such an approach. This approach comprised of the analysis of urine extracts and the investigation of collected nucleoside and modified nucleoside profiles by advanced statistical data processing tools such as principal component analysis (PCA), hierarchical cluster analysis (HCA), K-Nearest Neighbor method (kNN) and partial least squares-discriminant analysis with probabilistic function (p-PLS-DA). It has been shown that alterations of metabolite profiles in cancer diseases are mainly expressed by the fold change of the urine levels of most nucleosides. In addition, observed metabolite-to-metabolite ratios differ in urogenital cancer patients compared to healthy controls. The obtained relationships between urinary nucleoside profiles and the presence of cancer diseases have been evaluated. Discrimination of the cancer patients and the non-cancer healthy subjects is with 76.5% sensitivity and 80.2% specificity. The presented results prove the usefulness of the metabolomic approach in studying urinary nucleoside profiles with high diagnostic potency in urogenital cancer diseases. Profiles of urinary nucleosides might be employed as a reliable and convenient tool in the diagnostics of urogenital tract cancer diseases. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719449     DOI: 10.1016/j.jpba.2010.07.031

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

Review 1.  Emerging role of N4-acetylcytidine modification of RNA in gene regulation and cellular functions.

Authors:  R Karthiya; S Mohammed Wasil; Piyush Khandelia
Journal:  Mol Biol Rep       Date:  2020-11-10       Impact factor: 2.316

2.  Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.

Authors:  Kuangxun Li; Junzhe Liu; Xinyu Yang; Zewei Tu; Kai Huang; Xingen Zhu
Journal:  Biosci Rep       Date:  2021-12-22       Impact factor: 3.840

3.  NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma.

Authors:  Rongfang Wei; Xing Cui; Jie Min; Zigen Lin; Yanyan Zhou; Mengjie Guo; Xiaojuan An; Hao Liu; Siegfried Janz; Chunyan Gu; Hongbo Wang; Ye Yang
Journal:  Acta Pharm Sin B       Date:  2022-01-29       Impact factor: 14.903

4.  Prognostic and Immunological Role of mRNA ac4C Regulator NAT10 in Pan-Cancer: New Territory for Cancer Research?

Authors:  Chuanxi Yang; Tingting Wu; Jing Zhang; Jinhui Liu; Kun Zhao; Wei Sun; Xin Zhou; Xiangqing Kong; Jing Shi
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

5.  Urinary nucleosides as biomarkers of breast, colon, lung, and gastric cancer in Taiwanese.

Authors:  Wei-Yi Hsu; Chao-Jung Chen; Yu-Chuen Huang; Fuu-Jen Tsai; Long-Bin Jeng; Chien-Chen Lai
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

Review 6.  The Processing, Gene Regulation, Biological Functions, and Clinical Relevance of N4-Acetylcytidine on RNA: A Systematic Review.

Authors:  Gehui Jin; Mingqing Xu; Mengsha Zou; Shiwei Duan
Journal:  Mol Ther Nucleic Acids       Date:  2020-02-08       Impact factor: 8.886

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.